Circumvention of tumor multidrug resistance by a new annonaceous acetogenin: atemoyacin-B.

Abstract

AIM:

To explore the effect of atemoyacin-B (Ate) on overcoming multidrug resistance (MDR).

METHODS:

Bullatacin (Bul) was used as a positive control. Cytotoxic effects of Bul and Ate were studied with cell culture of human MDR breast adenocarcinoma cells, MCF-7/Dox and human KBv200 cells, and their parental sensitive cell lines MCF-7 and KB. Cytotoxicity was determined by tetrazolium (MTT) assay. The function of P-glycoprotein (P-gp) was examined by Fura 2-AM assay. Cellular accumulation of doxorubicin (Dox) was determined by fluorescence spectrophotometry. Apoptosis was measured by flow cytometry.

RESULTS:

IC50 of Ate for MCF-7/Dox, MCF-7, KBv200, and KB cells were 122, 120, 1.34, and 1.27 nmol.L-1, respectively. IC50 of Bul for MCF-7/Dox, MCF-7, KBv200, and KB cells were 0.60, 0.59, 0.04, and 0.04 nmol.L-1, respectively. The cytotoxicities of Bul and Ate to MDR cells were similar to those to parental sensitive cells. Bul and Ate markedly increased cellular Fura-2 and Dox accumulation in MCF-7/Dox cells, but not in MCF-7 cells. The rates of apoptosis in MDR cells were similar to those in sensitive cells induced by Ate.

CONCLUSION:

There was no cross-resistance of P-gp positive MCF-7/Dox and KBv200 cell lines to Bul and Ate as compared with their sensitive P-gp negative MCF-7 and KB cell lines. The mechanism of the circumvention of MDR was associated with the decrease of P-gp function and the increase of cellular drug accumulation in MDR cells.

• Authors: L W Fu, Q C Pan, Y J Liang, H B Huang
• Journal: Zhongguo yao li xue bao = Acta pharmacologica Sinica (Zhongguo Yao Li Xue Bao) Vol. 20 Issue 5 Pg. 435-9 (May 1999) ISSN: 0253-9756 [Print] China
• PMID: 10678092 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents, Phytogenic
• Fatty Alcohols
• Furans
• atemoyacin B
• bullatacin
• Doxorubicin
• 4-Butyrolactone
• Fura-2

Topics

• 4-Butyrolactone (analogs & derivatives, pharmacology)
• Adenocarcinoma (pathology)
• Antineoplastic Agents, Phytogenic (pharmacology)
• Apoptosis
• Breast Neoplasms (pathology)
• Doxorubicin (metabolism)
• Drug Resistance, Multiple
• Drug Resistance, Neoplasm
• Fatty Alcohols (pharmacology)
• Fura-2 (metabolism)
• Furans (pharmacology)
• Humans
• KB Cells (drug effects)
• Tumor Cells, Cultured (drug effects)